Objective Pemetrexed is a multitargeted anti-metabolite. Pemetrexed has been approved as the second-line treatment in non-small cell lung cancer. Our aim was to evaluate the clinical efficiency, the clinical benefit response rate and toxicity of pemetrexed ( combined with cisplatin) in treatment of advanced retreated non-small cell lung cancer. Methods 45 advanced retreated NSCLC patients received pemetrexed at a dose of 500 mg/m2, or combined with cisplatin at a dose of 25mg/m2, the chemotherapy was repeated every 21 days until disease progression or the occurrence of untolerant adverse reactions. Results The overall response rate was 31.11% , the clinical benefit rate was 62.22% , and the main toxic and adverse reactions were hematological toxicties and gastrointestinal reactions. Conclusion Pemetrexed is effective in treatment of advanced retreated non-small lung cancer and the toxicity can be well tolerated.%目的 观察培美曲塞单药(或联合顺铂)治疗复治晚期的非小细胞肺癌的临床疗效、临床获益率和毒副反应.方法 病理确诊45例复治晚期的非小细胞肺癌患者接受培美曲塞500 mg/m2化疗,或联合顺铂25mg/m221d为1个周期,重复直至疾病进展或出现不可耐受的毒副作用.结果 总有效率(CR+PR)为31.11％,临床获益率(CR+PR+ SD)为62.22％.主要毒副反应为骨髓抑制和胃肠反应.结论 培美曲塞治疗晚期复治的非小细胞肺癌取得较明显的临床获益率,且毒副反应可耐受.
展开▼
